Published May 23, 2016
Washington, DC—May 23, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Workshop 2—Risk-Sharing Agreements for Manufacturers and Commercial Payers in the United States: How Can Theory Help Practice? Design and Aligning Incentives Are Key—was held this afternoon in Washington, DC, USA. Workshop discussion leaders included:
  • Lou Garrison, PhD, ISPOR President-Elect and Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
  • Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK
  • Rajiv Mallick, PhD, Senior Director, Health Economics and Outcomes Research, BTG International Inc., West Conshohocken, PA, USA
  • Pete Fullerton, PhD, RPh, Principal, Strategic Pharmacy Innovations, Seattle, WA, USA
While there is significant interest in risk-sharing agreements, previous research has documented the limited use of these agreements in the US for both medicines and devices. Other research has identified a number of practical barriers, including the costs of reaching an agreement and the lack of adequate data infrastructure. The discussion leaders described the practical challenges to successful risk-sharing agreements and explained how theory could help structure appropriate incentives that address areas of uncertainty. The leaders covered five different (but complementary) theoretical frameworks, including value-of-information theory, money-back guarantees, real option theory, portfolio theory, and Bayes theorem. Presentations and slide decks from the ISPOR 21st Annual International meeting can be found here. Interested parties can follow news and developments from the meeting on social media using the hashtag #ISPORDC.


Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now